10/29/2010

Bristol-Myers Squibb has gained FDA approval for Sprycel as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia. The drug already was approved to treat those who do not respond to other drugs, including Novartis' Gleevec.

Related Summaries